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The guanylin peptide family
and the proposed
gastrointestinal–renal natriuretic
signaling axis
Thomas Mueller1 and Benjamin Dieplinger1
According to a proposed concept of a gastrointestinal–renal natriuretic
signaling axis, natriuretic peptides are released from the intestine into
the circulation in response to oral salt intake and act on the kidneys as
hormones to increase sodium excretion. The peptides guanylin and
uroguanylin and their precursors proguanylin and prouroguanylin,
respectively, have been suggested to be the mediators of this axis.
A study by Preston and co-workers, however, provides important
data not supporting this putative concept.
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Studies in the 1970s demonstrated that
an oral load of sodium evoked higher
natriuresis than did a similar intrave-
nous load of sodium in humans.1,2
These observations have contributed
to the concept of a gastrointestinal–
renal natriuretic signaling axis. Accord-
ing to this concept, natriuretic peptides
are released from the intestine into the
circulation in response to oral salt
intake and thereafter act on the kidneys
as hormones to increase sodium excre-
tion. During the past 20 years, two
members of the guanylin peptide
family, guanylin and uroguanylin, have
been suggested as candidates for mediat-
ing this proposed postprandial entero-
renal endocrine axis.3,4 However,
Preston et al.5 (this issue) now pro-
vide results from a high-quality experi-
mental study in healthy subjects that do
not support the existence of such an
acute gastrointestinal–renal natriuretic
signaling axis. Most importantly, the
authors of this work cast doubt on a
central role of guanylin peptide family
members in such an axis if it really
exists.
The guanylin peptide family has
several subclasses of peptides, including
guanylin and uroguanylin.6 The sources
of these peptides are the intestine and
the kidneys but also other epithelia.
Guanylin mRNA has been detected
mainly in the gastrointestinal tract in
numerous cell types and in the kidney.
Uroguanylin mRNA is, for example,
present in the gut, kidney, heart,
reproductive system, and brain. The
expression pattern of both peptides is
differential in the intestine: the highest
expression of guanylin occurs in the
ileum to the proximal colon, and of
uroguanylin in the jejunum.6 As in the
gut, guanylin and uroguanylin are not
equally expressed along the different
nephron segments. Guanylin is more
pronounced in the collecting duct, and
uroguanylin is present mostly in the
proximal tubule.6 In the classical point
of view, guanylin and proguanylin are
primarily thought to participate in the
regulation of salt and water homeostasis
in the intestine and the kidney.3,4,6
Guanylin peptides produced in the
intestine after ingestion of a salty meal
are secreted into the intestinal lumen.
In the intestine, guanylin and urogua-
nylin activate epithelial cells mainly
via the guanylate cyclase C receptor
with cyclic guanosine monophosphate
(cGMP) as second messenger.3,4,6
Activation of this pathway leads to the
secretion of Cl and HCO3
 and to
the inhibition of Naþ absorption,
which drives water secretion into the
intestinal lumen.4,6 These mechanisms
are probably involved in the regulation
of salt and water transport across the
intestinal epithelia and in the regu-
lation of intestinal pH. In addition,
guanylin and uroguanylin target the
renal tissue, eliciting natriuresis, kali-
uresis, and diuresis, along with increas-
ing urinary cGMP levels without
changes in glomerular filtration rate
or renal blood flow.3,4,6 Thus, guanylin
peptides presumably induce increased
urinary salt and water excretion in
order to prevent hypernatremia and
hypervolemia after enhanced salt
uptake exceeding the body’s physio-
logical requirements. In contrast to the
intestine, where the guanylate cyclase C
receptor seems to be the most important
receptor by far, guanylin and uroguany-
lin can activate different pathways along
the nephron. The guanylate cyclase C
receptor has been suggested to play a
minor role in the kidney, conceivably
restricted to the proximal tubule. In
the kidney, additional receptors with
different messenger systems are
activated by the guanylin peptides and
mediate complex effects on electrolyte
and water excretion.3,4,6 The molecular
identities of these renal receptors for
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guanylin and uroguanylin still remain to
be determined.
The genes for guanylin and
uroguanylin are located at human
chromosome 1 (localization 1p35–p34
and 1p34–p33, respectively).7,8 Both
peptides are produced by translation
as prepro-hormones. In humans, the
precursor of guanylin is synthesized as
prepro-guanylin consisting of 115
amino acids. Intracellular cleavage of
21 NH2-terminal residues leads to for-
mation of proguanylin with 94 amino
acids. Further extracellular proteolytic
processing reveals the small COOH-
terminal 15-amino acid peptide
guanylin and a 79-amino acid pro-
region. Similarly, human uroguanylin is
derived from prepro-uroguanylin
consisting of 112 amino acids. Post-
translational intracellular cleavage
reveals a 26-amino acid NH2-terminal
signal peptide and the 86-amino acid
prouroguanylin. Prouroguanylin is then
released into the extracellular space
and processed into the COOH-
terminal 16-amino acid peptide urogua-
nylin and a 70-amino acid pro-region
(or probably several smaller fragments).
In simplified terms, Figure 1 displays
the post-translational processing of both
polypeptides and their effects in the
intestine and the kidneys.
Guanylin and uroguanylin but not
proguanylin and prouroguanylin are
thought to be the biologically active
peptides.3,6 Human guanylin possesses
two disulfide bonds between the
cysteines in positions 4 to 12 and 7 to
15.3,6 Human uroguanylin also has two
disulfide bonds at the same positions.3,6
These disulfide bonds are essential for
the activity of the peptides. Both
proguanylin and prouroguanylin are
considered biologically inactive beca-
use of structural interactions between
the amino acid sequences related to
active peptides and the NH2-terminal
residues thereby covering the biologi-
cally active epitopes.9
With several assays published in
the literature, guanylin, uroguanylin,
proguanylin, and prouroguanylin can
be detected in human plasma. All four
peptides are freely filtered through
the glomerular barrier in the kidney.
However, urine contains only low
amounts of guanylin and proguanylin,
probably because of degradation by
chymotrypsin-like proteases or endo-
cytosis.3,6 In contrast, uroguanylin and
prouroguanylin can be found in
higher concentrations in the urine.
This is most likely the consequence
of a key structural property uniquely
found in uroguanylin peptides but
not in guanylin peptides that makes
uroguanylin peptides highly resistant
to attack by endoproteases such as
chymotrypsin.6
In terms of their natriuretic proper-
ties, the question is whether guanylin
and uroguanylin or proguanylin and
prouroguanylin, respectively, act as
hormones or have merely autocrine/
paracrine functions in the kidney. In
the first case the peptides should be
produced in the intestine in response
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Figure 1 | Post-translational processing of guanylin and uroguanylin and their proposed effects in the kidney and intestine. aa, amino
acids; cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate.
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to oral salt intake and could be trans-
ported via the circulation to the
kidneys and exert their effects in their
target cells along the nephron. In the
second case the peptides would be
produced in the kidney in response to,
for instance, hypernatremia and have
autocrine/paracrine functions in the
cells along the nephron. The results of
the study by Preston et al.5 (this issue)
do rather contradict the first case. The
authors of this study examined 15
healthy human volunteers and sought
to investigate whether an oral sodium
load is excreted more rapidly than
sodium given intravenously during
low- and high-sodium diets, and
whether serum concentrations of pro-
guanylin and prourogunaylin increase
because of the study-specific interven-
tions. Thus, the study addressed both
the concept of a gastrointestinal
sodium sensor and the potential role
of proguanylin and prourogunaylin as
mediators of natriuresis.
With the study protocol applied,
Preston et al.5 found that there was no
difference in the cumulative or hourly
natriuretic response to oral versus
intravenous sodium administration.
The authors acknowledge as a limi-
tation of their study that these findings
cannot entirely disprove the hypothesis
of the existence of a gastrointestinal–
renal natriuretic signaling axis per se.
Nevertheless, because the authors did
not find an increase of proguanylin and
prourogunaylin serum concentrations
in time course, the results of this
study—taken together—strongly argue
against a central role of proguanylin or
prourogunaylin in mediating a pro-
posed postprandial entero-renal endo-
crine axis. Thus, with the results of this
study, there is no indication of a
gastrointestinal sensor causing guanylin
peptide release into the circulation.
The evidence provided by the study
of Preston et al.5 rather points to the
view that the described renal effects of
guanylin and uroguanylin are mediated
by both peptides produced locally in
the kidney and secreted to the nephron
by cells lining the lumen. The peptides
could thereby act on their target cells
along the nephron.
Besides the role of guanylin and
uroguanylin or proguanylin and prour-
oguanylin, respectively, in the intestine
and the kidney of healthy people
as discussed, the peptides might also
have implications in a variety of
diseases. For example, increased plasma
guanylin and uroguanylin concentra-
tions were previously reported in
patients with renal failure.3,6 Recent
studies demonstrated that guanylin
peptides are also increased in urine
and/or plasma samples of patients with
heart failure. It has not been fully
established until now whether the
peptides have diagnostic and/or pro-
gnostic capability in such patients. It is
of course speculative, but perhaps
guanylin peptides may be of clinical
value in this condition, because it has
been suggested that cardiac natriuretic
peptides such as B-type natriuretic
peptide and guanylin peptides partici-
pate in a complementary or even
synergistic fashion in the regulation of
kidney function to maintain salt and
water homeostasis and, ultimately,
arterial blood pressure and volume.
Furthermore, previous studies provide
evidence to suggest that guanylin
and uroguanylin have nonclassical
roles, for example, olfactory functions,
cell cytostatic functions, and repro-
ductive functions.4,6 Moreover, uro-
guanylin (but not guanylin) might act
as part of a gut–brain axis that regulates
ingestion, energy homeostasis, and
body weight.10
In conclusion, the study by Preston
et al.5 and other recent work indicate
that the (patho)physiology of the
guanylin peptide family members
seems to be much more complicated
than the existing hypotheses have
suggested. Further intensive research is
necessary to clarify the role of guanylin
and uroguanylin or proguanylin and
prouroguanylin, respectively, in healthy
and diseased people.
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